Cargando…

Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients

Background Lack of data on balancing bleeding and thrombosis risk causes uncertainty about restarting anticoagulants after major bleeding. Anticoagulant reversal trials offer prospectively gathered data after major bleeding with well-documented safety events and restarting behavior. Objectives To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milling, Truman J., King, Ben, Yue, Patrick, Middeldorp, Saskia, Beyer-Westendorf, Jan, Eikelboom, John W., Crowther, Mark, Xu, Lizhen, Verhamme, Peter, Siegal, Deborah M., Connolly, Stuart J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322590/ https://www.ncbi.nlm.nih.gov/pubmed/33634446 http://dx.doi.org/10.1055/a-1400-6159

Ejemplares similares

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding
por: Little, Derek H.W., et al.
Publicado: (2021)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Preclinical and clinical data for factor Xa and “universal” reversal agents(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
por: Milling, Truman J., et al.
Publicado: (2016)

Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials
por: King, Ben, et al.
Publicado: (2020)

An anticoagulant that does not cause bleeding – an abrupt stop on the road to the Holy Grail
por: Meijers, Joost C. M., et al.
Publicado: (2019)

Pantoprazole for the Treatment of Peptic Ulcer Bleeding and Prevention of Rebleeding
por: van Rensburg, Christo J., et al.
Publicado: (2012)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding
por: Nagata, Naoyoshi, et al.
Publicado: (2017)

Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel
por: Fermann, Gregory J., et al.
Publicado: (2023)

Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals
por: Refaai, Majed A., et al.
Publicado: (2023)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
por: Hamulyák, Eva N., et al.
Publicado: (2020)

Rebleeding Rate and Risk Factors for Rebleeding after Device-Assisted Enteroscopy in Patients with Obscure Gastrointestinal Bleeding: A KASID Multicenter Study
por: Kim, Yuna, et al.
Publicado: (2022)

Clinical Characteristics and Risk Factors for Rebleeding in Patients with Obscure Gastrointestinal Bleeding
por: Baba, Yuki, et al.
Publicado: (2020)

Predictors of rebleeding and in-hospital mortality in patients with nonvariceal upper digestive bleeding
por: Lazăr, Daniela Cornelia, et al.
Publicado: (2019)

Risk Factors for Late Rebleeding of Colonic Diverticular Bleeding in Elderly Individuals
por: Sato, Yoshinori, et al.
Publicado: (2021)

Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis
por: Pfisterer, Nikolaus, et al.
Publicado: (2021)

A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?
por: Milling, Truman J., et al.
Publicado: (2020)

Rebleeding after Stent Grafting for the Celiac Artery Bleeding following Extended Pancreaticoduodenectomy
por: Ohta, Kengo, et al.
Publicado: (2013)

Nomogram-based prediction of rebleeding in small bowel bleeding patients: the ‘PRSBB’ score
por: Uchida, Genta, et al.
Publicado: (2018)

Risk factors for rebleeding in patients with obscure gastrointestinal bleeding from southern China
por: Liu, Boying, et al.
Publicado: (2021)

Transarterial Embolization for Active Gastrointestinal Bleeding: Predictors of Early Mortality and Early Rebleeding
por: Extrat, Chloé, et al.
Publicado: (2022)

Construction of a prediction model for rebleeding in patients with acute upper gastrointestinal bleeding
por: Zhuang, Yangping, et al.
Publicado: (2023)

The Tick-Derived Anticoagulant Madanin Is Processed by Thrombin and Factor Xa
por: Figueiredo, Ana C., et al.
Publicado: (2013)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
por: Eikelboom, John W., et al.
Publicado: (2015)

Reproductive issues in women on direct oral anticoagulants
por: Beyer‐Westendorf, Jan, et al.
Publicado: (2021)

Impact of different dose reduction criteria for anti‐Xa direct oral anticoagulants on bleeding complications: A single center observational study
por: Fukaya, Hidehira, et al.
Publicado: (2022)

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
por: Yentz, Sarah, et al.
Publicado: (2015)

Factors Associated with Rebleeding in Patients with Peptic Ulcer Bleeding: Analysis of the Korean Peptic Ulcer Bleeding (K-PUB) Study
por: Kim, Joon Sung, et al.
Publicado: (2018)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
por: Shaw, Joseph R., et al.
Publicado: (2023)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
por: Connolly, Stuart J., et al.
Publicado: (2013)

Rebleeding rate after interventional therapy directed by capsule endoscopy in patients with obscure gastrointestinal bleeding
por: Endo, Hiroki, et al.
Publicado: (2008)

Cancer, platelet distribution width, and total protein levels as predictors of rebleeding in upper gastrointestinal bleeding
por: Tatlıparmak, Ali Cankut, et al.
Publicado: (2022)

Associations Between Endoscopic Primary Prophylaxis and Rebleeding in Liver Cirrhosis Patients with Esophagogastric Variceal Bleeding
por: Gao, Yanying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_29ptleml74j5jn9raeg5284a4j